Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,633 signal articles · 27 in last 24h · 155,734 total before filter · latest 1h ago
27last 24h
847last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro195Earnings106M&A122Regulatory20Product21Analyst19
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
D-Wave Quantum’s Revenue Hasn’t Moved in Two Years. Here’s Why That’s a Problem.
TIKR4d agoneutral
D-Wave Quantum’s Revenue Hasn’t Moved in Two Years. Here’s Why That’s a Problem.

Key TakeawaysD-Wave’s quarterly revenue has stayed inside a roughly $2 million to $4 million band in seven of the last eight quarters, with the $15 million system sale booked in Q1 2025 the lone exception, even as management points to a 59% jump in Q2 bookings and 668% growth in remaining performance obligations. Total operating expenses climbed from $21.

What Does Frontline (FRO) Special Q2 2026 Dividend Mean For Investors?
Simply Wall St.4d agoneutral
What Does Frontline (FRO) Special Q2 2026 Dividend Mean For Investors?

Frontline (NYSE:FRO) announced that its Board has approved a special one time cash dividend alongside its regular Q2 2026 payout. The extra distribution is described as a single event, separate from the tanker operator's usual recurring dividend policy. Management framed the special dividend as a direct cash return to shareholders that reflects the group's current financial position. This special one time dividend for the second quarter of 2026 is an important development to weigh against...

What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?
Simply Wall St.4d agoneutral
What Could Johnson & Johnson (JNJ) Gain From Its New Immunology Push?

Johnson & Johnson (NYSE: JNJ) received FDA approval for ICOTYDE (icotrokinra) to treat moderate to severe plaque psoriasis in the U.S. ICOTYDE targets the IL-23 receptor and is in Phase III clinical trials for a potential psoriatic arthritis indication. The new therapy extends Johnson & Johnson's immunology pipeline beyond oncology and MedTech into chronic inflammatory skin and joint conditions. The ICOTYDE psoriasis approval and psoriatic arthritis Phase III program deserves weighing...

TMC The Metals (TMC) Climbed, So What Is Driving Attention Now?
Simply Wall St.4d agoneutral
TMC The Metals (TMC) Climbed, So What Is Driving Attention Now?

TMC the metals (NasdaqGS:TMC) is stepping in front of investors again, with management presenting at Morgan Stanley's 14th Annual Laguna Conference on September 15 and the Water Tower Research Virtual Insights Conference on September 22. Recent trading has been choppy for TMC the metals, with a 1-day share price return of 9.52% and a 7-day share price return of 8.09% following a 30-day share price return that declined 13.57%. That near term volatility sits against a year to date share price...

Axcelis Technologies (ACLS) Is Up 7.4% After Announcing Major Korean Manufacturing Expansion Plan - Has The Bull Case Changed?
Simply Wall St.4d agoneutral
Axcelis Technologies (ACLS) Is Up 7.4% After Announcing Major Korean Manufacturing Expansion Plan - Has The Bull Case Changed?

Axcelis Technologies has announced plans to invest US$35,000,000 in a new 200,000-square-foot ion implantation equipment manufacturing facility in Pyeongtaek, Korea, with integrated cleanrooms, warehousing, and training capabilities, following an investment declaration ceremony with Korean government bodies and production targeted to start in the second half of 2028. This expansion adds a significant Asian manufacturing hub that could enhance Axcelis’s ability to respond quickly to customer...

Should Boeing Stock Investors Worry About Its Money-Losing Jet Business?
Trefis4d agoneutral
Should Boeing Stock Investors Worry About Its Money-Losing Jet Business?

If you own Boeing (BA), the worry is whether its commercial airplane business can earn money on the jets it sells. In the second quarter of fiscal 2026, that business lost money. Its operating margin was negative 2.7%, meaning costs ran above sales. The jet business brought in nearly half of Boeing's revenue for the quarter. That makes its margin the number that matters most for Boeing's profits.

Why Meta's Muse AI agent is soaring in popularity
Yahoo Finance Video4d agobullishVIDEO
Why Meta's Muse AI agent is soaring in popularity

Meta's (META) new Muse AI app is topping charts. Yahoo Finance Breaking Business News Reporter Jake Conley, Yahoo Finance Senior Autos Reporter Pras Subramanian, and Yahoo Finance's Julie Hyman outline Muse's features and risks.

Sysco (SYY): Buy, Sell, or Hold Post Q2 Earnings?
StockStory4d agoneutral
Sysco (SYY): Buy, Sell, or Hold Post Q2 Earnings?

Sysco currently trades at $78.11 per share and has shown little upside over the past six months, posting a small loss of 4.3%. The stock also fell short of the S&P 500’s 16.2% gain during that period.